Clinical Trials · NCT07754045

Evaluating the Efficacy and Safety of LUM-201 Plus Semaglutide Versus Semaglutide Plus Placebo in Older Obese Adults

Not Yet RecruitingPhase 2Semaglutide (Investigational)
Phase
Phase 2
Recruitment status
Not Yet Recruiting
Sponsor
Lumos Pharma
Enrollment
202
Start date
Feb 2027
Locations
See registry
Primary endpoint
Proportion of participants with Short Physical Performance Battery (SPPB) score ≤ 7 at Week 26.
View Semaglutide compound reference